ASCO’s TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators


Get Permission

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drugs, more than 100 sites in 20 states, new partnerships, and a -revised protocol to lower the age of eligibility.

Recently, eight new centers in 36 locations signed on to begin offering the TAPUR Study within the next few months:

  • Fox Chase Cancer Center, Pennsylvania: 1 site
  • Inova Schar Cancer Institute, Inova Health System, Virginia: 6 sites
  • Sutter Cancer Research Consortium, Northern California: 9 sites
  • The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Southern California: 3 sites
  • The University of Texas MD Anderson Cancer Center, Texas: 5 sites
  • The University of Alabama at Birmingham Comprehensive Cancer Center, Alabama: 1 site
  • Sylvester Comprehensive Cancer Center, University of Miami, Florida: 7 sites
  • Winship Cancer Institute of Emory University, Georgia: 4 sites

At these sites, a total of 17 drugs yielding 15 different targeted therapy options (some drugs are used in combination) are available, which are provided by the seven pharmaceutical companies currently participating: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Merck, and Pfizer.

In addition, the study protocol, with cooperation from stakeholders and approved by the Institutional Review Board, has been revised to lower the age of eligibility into the trial from 18 to 12 years of age, where there is a defined adolescent dose for the study drugs. 

In an effort to expand eligibility and facilitate logistics, the TAPUR team is engaging in several new collaborations with:

  • Cure-One™ (formerly MED-C, The Molecular Evidence Development Consortium) “Patients Diagnosed with Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A Cure-One Observational Registry (N1 Registry™)”: Through this collaboration, both ASCO and Cure-One will be in regular communication and will develop ways to identify and support patients who are eligible to participate in both initiatives. 
  • Caris Life Sciences® and Foundation Medicine, Inc.: These two organizations are the first to receive the new “optimized for TAPUR reporting” designation, meaning that they provide a report organized to optimize identification of genomic alterations that match to TAPUR Study drugs. 
  • Canadian Cancer Trials Group (CCTG) and WIN Consortium: Both CCTG and WIN Consortium have studies in development that are based on TAPUR, and ASCO aims to collaborate with them to share study results to accelerate learning. 

The objective for the TAPUR Study is to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of indications already approved by the U.S. Food and Drug Administration. Patients, researchers, and practices can find study information such as general eligibility criteria, participating clinical sites, and contact information for the study team at www.TAPUR.org. ■

© 2017. American Society of Clinical Oncology. All rights reserved.



Advertisement

Advertisement



Advertisement